Byooviz Injection, Solution
Product Images NDC 82667-018

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Byooviz (NDC 82667-018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Harrow Eye, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Sb11 01)

Illustration showing how to use a syringe to withdraw medication from a vial. The vial is tilted at an angle while the syringe needle is inserted, with a downward arrow indicating the direction of the syringe plunger.*

FDA Label Image

Figure (Sb11 02)

An instructional illustration showing a syringe extracting solution from a vial by inserting the needle into the vial's stopper. An arrow above the syringe indicates the upward drawing motion.*

FDA Label Image

Figure (Sb11 03)

An instructional illustration showing the steps for preparing an intravitreal injection using a syringe. The images depict removing the cap, rotating or adjusting the needle cover, and then removing the needle cap upward to expose the needle, likely for use with Byooviz (ranibizumab-nuna) injection solution.*

FDA Label Image

Figure (Sb11 04)

An instructional illustration showing two hands preparing a syringe with an injection solution. One hand holds the syringe upright while the other hand appears to be flicking or tapping the syringe barrel, likely to remove air bubbles before intravitreal injection.*

FDA Label Image

Figure (Sb11 05)

An illustration showing a syringe with a needle, highlighting a 0.05 mL volume marking on the syringe barrel, likely indicating the intended injection volume for administration.*

FDA Label Image

Figure 1 (Sb11 06)

This image contains two line graphs labeled AMD-1 and AMD-2, showing mean change in visual acuity (letters) over 24 months. Both graphs plot positive and negative trends with black square and circle markers, indicating visual acuity changes over time in months.*

FDA Label Image

Figure (Sb11 07)

Byooviz 10 mg/mL injection, solution in a single-dose vial for intravitreal use. The label includes the proprietary name Byooviz and the active ingredient ranibizumab-nuna. The labeler is Harrow Eye, LLC, and the product NDC is 82667-018. The vial features a green cap and clear glass container with printed text on the label.*

FDA Label Image

Figure (Sb11 08)

Byooviz 10 mg/mL intravitreal injection solution in a glass vial with a gray rubber stopper and aluminum seal. The label includes the product name, active ingredient ranibizumab-nuna, strength, and the labeler Harrow Eye, LLC.*

FDA Label Image

Figure (Sb11 09)

Byooviz 10 mg/mL injection, solution. This intravitreal injection is supplied in a clear glass vial with a purple cap and has a white label showing the product name Byooviz, active ingredient ranibizumab-nuna, and manufacturer Harrow Eye, LLC. The vial appears intended for single use.*

FDA Label Image

Figure (Sb11 10)

Byooviz 10 mg/mL ranibizumab-nuna intravitreal injection, solution vial. The clear vial has a white cap and is labeled with the product name, strength, dosage form, and manufacturer Harrow Eye, LLC. The label includes dosage instructions and handling information.*

FDA Label Image

Figure 2 (Sb11 11)

A line chart titled 'AMD-3' showing mean change in visual acuity (in letters) over 12 months. The y-axis ranges from -20 to 10 letters, and the x-axis shows months from 0 to 12. Two data series are displayed: one increasing from 0 to about 5 letters then declining slightly to 0, and another decreasing steadily from 0 to around -16 letters by month 12.*

FDA Label Image

Figure (Sb11 12)

Byooviz 10 mg/mL intravitreal injection solution label. The label shows the product name Byooviz with ranibizumab-nuna as the generic name, identifying it as a human prescription drug. The labeler is Harrow Eye, LLC. The packaging includes safety and storage information along with usage instructions, presented primarily in black and purple on a white background.*

FDA Label Image

Figure (Sb11 13)

Byooviz (ranibizumab-nuna) injection, solution 10 mg/mL label for intravitreal use. The label includes the proprietary and generic names, strength, dosage form, route of administration, and the labeler Harrow Eye, LLC. The image also shows portions of text and handling instructions, along with barcode and NDC 82667-018.*

FDA Label Image

Figure 3 (Sb11 14)

A line graph titled 'AMD-4' showing mean change in visual acuity in letters over 24 months. The x-axis represents time in months, and the y-axis represents mean change in visual acuity (letters). Two data series are plotted, one peaking near 10 letters and the other near 8 letters, with values 9.1 and 7.9 respectively at 24 months.*

FDA Label Image

Figure (Sb11 15)

Byooviz 10 mg/mL intravitreal injection solution vial label. The label shows the brand name Byooviz, the generic name ranibizumab-nuna, the dosage strength of 10 mg/mL, and dosage form as injection solution. It is labeled for intravitreal use. The labeler is Harrow Eye, LLC. The vial is clear with a pink cap.*

FDA Label Image

Figure (Sb11 16)

The image shows the carton packaging for Byooviz (ranibizumab-nuna) injection, solution, 10 mg/mL. It includes details such as the brand and generic name, dosage form as intravitreal injection, and the labeler, Harrow Eye, LLC. The package indicates it is a human prescription drug and includes storage and handling instructions visible on one side.*

FDA Label Image

Figure 4 (Sb11 17)

A bar chart showing the distribution of the number of injections received by patients, with the x-axis labeled 'Number of Injections' and the y-axis labeled 'Percentage of Patients (%)'. The chart indicates a mean of 10.3 injections per patient.*

FDA Label Image

Figure 5 (Sb11 18)

Two line graphs labeled RVO-1 and RVO-2 showing mean change in visual acuity (letters) over six months. Each graph has two lines: one with black squares showing positive increases, and one with open circles showing minimal change. Numerical improvements at 6 months are +18.3 and +7.3 for RVO-1, +14.9 and +0.8 for RVO-2 respectively.*

FDA Label Image

Figure (Sb11 19)

Byooviz 10 mg/mL injection, solution in a single-dose vial. The label shows handwritten details including lot number, expiration date, and concentration. The product is distributed by Harrow Eye, LLC and intended for intravitreal administration.*

FDA Label Image

Figure (Sb11 20)

Chemical structure diagram depicting the molecular structure of ranibizumab-nuna, the active ingredient in Byooviz 10 mg/mL intravitreal injection by Harrow Eye, LLC.*

FDA Label Image

Figure (Sb11 21)

Byooviz 10 mg/mL injection, solution in a glass vial with blue and white labeling. The vial displays the proprietary name Byooviz and the labeler Harrow Eye, LLC. This intravitreal injection contains the active ingredient ranibizumab-nuna.*

FDA Label Image

Figure (Sb11 22)

Chemical structure of ranibizumab-nuna, the active ingredient in Byooviz 10 mg/mL intravitreal injection solution by Harrow Eye, LLC.*

FDA Label Image

Figure 6 (Sb11 23)

A line graph showing mean change in BCVA from baseline (letters ETDRS) over three months. It compares three groups: Ranibizumab Group 1, Ranibizumab Group 2, and Control (vPDT). Both Ranibizumab groups show increasing improvement up to about 12 letters, while Control shows minimal change, stabilizing near 1 letter.*

FDA Label Image

Principal Display Panel (0.5 mg Vial Carton)

Byooviz 0.5 mg injection carton label for ranibizumab-nuna, a single-dose intravitreal injection vial. The label includes dosage and storage instructions, manufacturer information including Harrow Eye, LLC and Samsung Bioepis, and a barcode. It highlights that the product must be refrigerated and protected from light, with no preservatives. The label also notes the requirement of a 5-micron sterile filter needle for preparation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.